Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

⚠ Preprint — not yet peer-reviewed alzhub usefulness score 16 out of 100. Down syndrome and Alzheimer's

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Background Adults with Down syndrome (DS) are at risk for Alzheimer’s disease (AD). Recent natural history cohort studies have characterized AD biomarkers, with a focus on PET amyloid-beta (Aβ) and PET tau. Leveraging these well-characterized biomarkers, the present study examined the timeline to symptomatic AD based on estimated years since reaching Aβ+, referred to as “amyloid age”, and in relation to tau in a large cohort of individuals with DS.

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study of 167 participants. This cohort study of 167 adults with Down syndrome examined the timeline to symptomatic Alzheimer's disease based on estimated years since reaching amyloid positivity and in relation to tau. It describes biomarker timing only and tests no treatment or prevention.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Schworer, E. K., Zammit, M. D., Wang, J., Handen, B. L., Betthauser, T., Laymon, C. M., et al. (2024). Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome. medRxiv. https://doi.org/10.1101/2024.08.08.24311702

Vancouver

Schworer EK, Zammit MD, Wang J, Handen BL, Betthauser T, Laymon CM, et al. Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome. medRxiv. 2024. doi:10.1101/2024.08.08.24311702.

BibTeX

@article{schworer2024-f00bce0d,
  author  = {Schworer, E. K. and Zammit, M. D. and Wang, J. and Handen, B. L. and Betthauser, T. and Laymon, C. M. and Tudorascu, D. L. and Cohen, A. D. and others},
  title   = {{Amyloid age and tau PET timeline to symptomatic Alzheimer’s disease in Down syndrome}},
  journal = {medRxiv},
  year    = {2024},
  doi     = {10.1101/2024.08.08.24311702},
  url     = {https://doi.org/10.1101/2024.08.08.24311702}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

This cohort study of 167 adults with Down syndrome examined the timeline to symptomatic Alzheimer's disease based on estimated years since reaching amyloid positivity and in relation to tau. It describes biomarker timing only and tests no treatment or prevention.

Study details

How this study scored 16/100
How this study's score is builtJournal tier 2 of 10; Journal's citation record 0 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 4 of 10; How recent 4 of 5; Sample size 2 of 4; Effect reported 0 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 0 of 7; Citations per year 0 of 5; Impact for its field and year left out, no data; Cited by studies here 0 of 6; Still being cited 0 of 4; Senior author's track record 2 of 4; Institution's track record 2 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 1 of 2; Free to read 0 of 2. 32 of the 94 points it could be judged on, which is 34 of 100. Raw total 34 of 100, shown as 16 because this is not a peer-reviewed research article.raw total 34 of 100capped at 16 — hatched points do not count

Preprint — not yet peer-reviewed. It scored 34 on the same rubric, but non-peer-reviewed sources are capped at 16, so it shows as 16. Scored zero for effect reported and randomized / blinded because the record does not state it. We have no data on impact for its field and year, so that was left out: it earned 32 of the 94 points we could judge it on, which is 34 out of 100.

ComponentPointsWhy
Journal tier 2 / 10 Tier 4 — not a peer-reviewed journal (medRxiv)
Journal's citation record 0 / 4 Not a journal article, so the journal's record does not count
Study design 7 / 12 A cohort study following people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 4 / 10 Preprint — not yet peer-reviewed. Hosted on a preprint server.
How recent 4 / 5 2024 — within 3 year(s) of the newest study here
Sample size 2 / 4 167 participants
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 0 / 7 Cited 0 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.0 citations a year over 4 year(s) since 2024
Impact for its field and year — / 6 No field-weighted citation impact (OpenAlex has none yet) — left out of this score
Cited by studies here 0 / 6 No other study in this library cites it
Still being cited 0 / 4 Cited 0 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 2 / 4 Last-listed author Sigan L. Hartley: h-index 43 (OpenAlex, whole career)
Institution's track record 2 / 3 University of Cambridge: institution h-index 1,973 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 2 countries
Indexed in PubMed 1 / 2 Not in PubMed, but has a DOI
Free to read 0 / 2 Behind a paywall — scores zero
Points 32 / 94 Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 32 of the 94 points we could judge it on is 34 out of 100.
Total 34 / 100 Capped to 16 because this is not a peer-reviewed article.

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 14.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →